Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanborn

Showing results (941-950 of 996) with videos related to

Pageof 100
Sort By:
Nature Genetics|September 8, 2015
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayA Hunter Shain, Maria Garrido, Thomas Botton, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapyHannah Reimann, Andrew Nguyen, J Zachary Sanborn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2015
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosomeF Favero, N McGranahan, M Salm, et al.
Cell|October 7, 2017
Cohesin Loss Eliminates All Loop DomainsSuhas S P Rao, Su-Chen Huang, Brian Glenn St Hilaire, et al.
Research Square|January 16, 2026
Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid ProteinsJalees Rehman, Marcin Kwissa, Manikannan Mathayan, et al.
European Heart Journal|February 23, 2010
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force CriteriaFrank I Marcus, William J McKenna, Duane Sherrill, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2020
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaUmair Mahmood, Andrew Bang, Yu-Hui Chen, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Circulation|February 23, 2010
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteriaFrank I Marcus, William J McKenna, Duane Sherrill, et al.
Pageof 100

Showing results (941-950 of 996) with videos related to

Sort By:
Pageof 100
Nature Genetics|September 8, 2015
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayA Hunter Shain, Maria Garrido, Thomas Botton, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapyHannah Reimann, Andrew Nguyen, J Zachary Sanborn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2015
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosomeF Favero, N McGranahan, M Salm, et al.
Cell|October 7, 2017
Cohesin Loss Eliminates All Loop DomainsSuhas S P Rao, Su-Chen Huang, Brian Glenn St Hilaire, et al.
Research Square|January 16, 2026
Persistent Immune Dysregulation during Long COVID is Manifested in Antibodies Targeting Envelope and Nucleocapsid ProteinsJalees Rehman, Marcin Kwissa, Manikannan Mathayan, et al.
European Heart Journal|February 23, 2010
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force CriteriaFrank I Marcus, William J McKenna, Duane Sherrill, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2020
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaUmair Mahmood, Andrew Bang, Yu-Hui Chen, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Circulation|February 23, 2010
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteriaFrank I Marcus, William J McKenna, Duane Sherrill, et al.
Pageof 100